Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyDose: Dose-escalated IMPT for Stage III NSCLC
NCT06484491Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Severe (grade 3+) adverse effects at 365 days. Started Sep 2025; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06484491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484491.